Jazz Pharmaceuticals PLC 10-Q quarterly reports

Jazz Pharmaceuticals plc announced its second quarter 2026 financial results, showcasing significant revenue increases driven by its key sleep and epilepsy medications, alongside progress in its oncology pipeline.

Jazz Pharmaceuticals reports strong Q1 2026 results with significant revenue growth driven by Xywav and oncology products, alongside a substantial gain from a PRV sale.

Jazz Pharmaceuticals reported a 7% increase in total revenues for Q3 2025, driven by strong performance from Xywav and Epidiolex, alongside new product approvals, despite ongoing litigation costs and competitive pressures.

Jazz Pharmaceuticals reported a significant net loss in Q2 2025, primarily driven by a large in-process R&D expense from the Chimerix acquisition and Xyrem antitrust litigation settlements, despite modest revenue growth.

Jazz Pharmaceuticals updates its executive severance benefit plan and files its Q1 2025 report, revealing key financial metrics and strategic developments.

Jazz Pharmaceuticals' Q3 2024 results show revenue growth driven by Xywav and strategic investments in research and development.

Jazz Pharmaceuticals reported its second quarter 2024 financial results, highlighting revenue growth driven by key products like Xywav and Epidiolex, while facing challenges from generic competition for Xyrem.

Jazz Pharmaceuticals' first quarter of 2024 saw a decrease in net product sales, offset by increased royalties and contract revenues, and a net loss of $14.6 million.